SEC Form 4 · accession 0001104659-18-017502
Mersana Therapeutics, Inc. · MRSN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
David A Spellman
Officer — Chief Financial Officer
Period of report
Mar 12, 2018
Accepted (ET)
Mar 14, 2018 · 4:49 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001442836
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $13.97 | Mar 12, 2018 | A | 150,000 | A | — | Mar 12, 2021 | Common Stock | 150,000 | 150,000 | D |
Explanation of responses
- F1The option will vest as to 25% of the shares on the first anniversary of the grant date and in equal quarterly installments over the next three years.